<div class="articleHeader">
<div xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:exsl="http://exslt.org/common" class="doi">Thromb Haemost 2012; 108(02): 201-202<br>DOI: 10.1160/TH12-05-0330</div>
<div class="articleType">
<div>Invited Editorial Focus</div>
</div>
<span class="articleCategories">Schattauer GmbH </span>
<h1>Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban</h1>
<span id="authorlist"><span class="author">
<div class="name">Marcel Levi</div>
<div class="affiliation">
<sup>1
 
</sup>Department of Medicine, Academic Medical Center, University of Amsterdam, The Netherlands</div>
<div class="affiliation"></div>
</span><a class="toggle-affiliation-infos" href="#">› Author Affiliations<span class="verbum"></span></a></span>
<div class="toggleMenu articleToggleMenu">
<div class="toggleButton">Further Information<div class="toggleContent">
<div class="wrapper twoCols">
<div class="col">
<h3>Publication History</h3>
<p>Received:
20 May 2012<br>
<br>Accepted:
21 May 2012<br>
<br>Publication Date:<br>25 November 2017 (online)</p>
</div>
</div>
</div>
</div>
</div>
</div><ul class="tabBar borderBottom" id="articleTabs">
<li class="tab active">
<a href="#abstract">Abstract</a>
</li>
<li class="tab">
<a href="/products/ejournals/html/10.1160/TH12-05-0330">Full Text</a>
</li>
<li class="tab">
<a href="#references">References</a>
</li>
</ul><div id="sections">
<section id="abstract">
<div class="articleFunctions"> <input value="ai10.1160/TH12-05-0330,10.1160/TH12-05-0330" name="ai" type="hidden">
<div style="display: none" id="sfx10.1160/TH12-05-0330">
<a id="sfxServer" data-href="?id=doi:10.1160/TH12-05-0330&sid=Thieme:Connect&jtitle=Thrombosis and Haemostasis&issue=08&volume=108&date=2012&issn=0340-6245&spage=201&epage=202&aulast=Levi&aufirst=Marcel&__char_set=utf8&atitle=Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban" target="sfx"><span class="articleAccessLabel sfx"><img id="sfxImageUrl" src="" alt="SFX Search" height="15" width="52"></span></a>
</div> <a style="display: none" href="/products/ejournals/buyDocument/10.1160/TH12-05-0330" class="gotoLink" id="sasLink">Buy Article</a> <a onClick="RightslinkPopUp("2567-689X", "Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban", "11/25/2017", "Marcel Levi", "", "10.1160/TH12-05-0330", "201", "202", "108", "08", "")" class="gotoLink" href="javascript:;">Permissions and Reprints</a>
</div>
<figure style="margin-left: 30px" class="floatRight">
<a data-cssClass="previewOverlay" href="https://www.thieme-connect.de/media/10.1055-s-00035024/201202/lookinside/10-1160-th12-05-0330-1.jpg" class="zoomFunction alignLeft"><img src="https://www.thieme-connect.de/media/10.1055-s-00035024/201202/lookinside/thumbnails/10-1160-th12-05-0330-1.jpg"></a>
<figcaption></figcaption>
</figure>
<p> </p>
<p>Editorial on ► Marlu et al. <a href="10-1160-th12-03-0179.xml">Thromb Haemost 2012; 108: 217-224</a>.</p>
<div id="trendmd-suggestions"></div>
</section>
<section id="htmlfulltext"> </section>
<section id="references">
<a name=""></a>
<ul class="literaturliste">
<a name="N109CD"></a>
<li>
<h3>References</h3>
</li>
<li>
<a name="JR17822-1"></a><strong>1</strong>
Ahrens I,
Lip GY,
Peter K.
New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-1/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="/products/ejournals/abstract/10.1160/TH09-05-0327">Article in Thieme Connect</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/20539909">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=New oral anticoagulant drugs in cardiovascular disease">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-2"></a><strong>2</strong>
Turpie AG,
Lassen MR,
Eriksson BI.
et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105: 444-453. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-2/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="/products/ejournals/abstract/10.1160/TH10-09-0601">Article in Thieme Connect</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/21136019">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-3"></a><strong>3</strong>
Mannucci PM,
Levi M.
Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-2311. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-3/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://doi.org/10.1056/NEJMra067742">Crossref</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/17538089">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Prevention and treatment of major blood loss">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-4"></a><strong>4</strong>
Sie P,
Samama CM,
Godier A.
et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011; 104: 669-676. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-4/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://doi.org/10.1016/j.acvd.2011.09.001">Crossref</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/22152517">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-5"></a><strong>5</strong>
Pengo V,
Crippa L,
Falanga A.
et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-5/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="/products/ejournals/abstract/10.1160/TH11-05-0358">Article in Thieme Connect</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/21946939">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA)">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-6"></a><strong>6</strong>
Levi MM,
Eerenberg E,
Lowenberg E.
et al. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med 2010; 68: 68-76. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-6/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/20167958">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-7"></a><strong>7</strong>
Levi M,
Eerenberg E,
Kamphuisen PW.
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011; 09: 1705-1712. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-7/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://doi.org/10.1111/j.1538-7836.2011.04432.x">Crossref</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/21729240">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-8"></a><strong>8</strong>
Levi M,
Eerenberg E,
Kamphuisen PW.
Periprocedural reversal and bridging of anticoagulant treatment. Neth J Med 2011; 69: 268-273. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-8/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/21868810">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Periprocedural reversal and bridging of anticoagulant treatment">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-9"></a><strong>9</strong>
Sorensen B,
Ingerslev J.
A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 2006; 96: 446-453. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-9/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="/products/ejournals/abstract/10.1160/TH06-04-0205">Article in Thieme Connect</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/17003921">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-10"></a><strong>10</strong>
Marlu R,
Hodaj E,
Paris A.
et al. Effect of non-specific reversal agents on anticoagulant activity of Dabigatran and Rivaroxaban: a randomised crossover ex-vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217-224. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-10/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="/products/ejournals/abstract/10.1160/TH12-03-0179">Article in Thieme Connect</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/22627883">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Effect of non-specific reversal agents on anticoagulant activity of Dabigatran and Rivaroxaban: a randomised crossover ex-vivo study in healthy volunteers">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-11"></a><strong>11</strong>
Godier A,
Miclot A,
Le Bonniec B.
et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology 2012; 116: 94-102. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-11/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://doi.org/10.1097/ALN.0b013e318238c036">Crossref</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/22042412">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-12"></a><strong>12</strong>
Fukuda T,
Honda Y,
Kamisato C.
et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost 2012; 107: 253-259. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-12/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="/products/ejournals/abstract/10.1160/TH11-09-0668">Article in Thieme Connect</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/22186946">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-13"></a><strong>13</strong>
Zhou W,
Schwarting S,
Illanes S.
et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-13/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://doi.org/10.1161/STROKEAHA.111.624650">Crossref</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/21998060">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-14"></a><strong>14</strong>
Eerenberg ES,
Kamphuisen PW,
Sijpkens MK.
et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-14/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://doi.org/10.1161/CIRCULATIONAHA.111.029017">Crossref</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/21900088">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-15"></a><strong>15</strong>
Bijsterveld NR,
Moons AH,
Boekholdt SM.
et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-15/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="https://doi.org/10.1161/01.CIR.0000038501.87442.02">Crossref</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/12427650">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-16"></a><strong>16</strong>
Woltz M,
Levi M,
Sarich TC.
et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemostas 2004; 91: 1090-1096. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-16/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a onClick="pubmed('','Thromb Haemostas','2004','91','1090')" href="#">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers">Google Scholar</a>
</div>
</div>
</li>
<li>
<a name="JR17822-17"></a><strong>17</strong>
Van Rijn J,
Stangier J,
Haertter S.
et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127. <div class="referenceLinks">
<a href="/products/ejournals/ris/10.1160/TH12-05-0330/id/JR17822-17/BIB">
<div class="referenceLinkRis"></div>
</a>
<div class="referenceLinkText">
<a target="linkout" href="/products/ejournals/abstract/10.1160/TH09-11-0758">Article in Thieme Connect</a><a target="linkout" href="https://pubmed.ncbi.nlm.nih.gov/20352166">PubMed</a><a target="linkout" href="https://scholar.google.com/scholar_lookup?title=Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity">Google Scholar</a>
</div>
</div>
</li>
</ul>
<br>
</section>
<section id="images"> </section>
<section id="supmat">
<ul class="tabBar borderBottom" id="supmatTabs"></ul>
<div class="tabContentContainer"></div>
</section>
</div>
